⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IBRX News
ImmunityBio, Inc. Common Stock
NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security
businesswire.com
IBRX
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”
businesswire.com
IBRX
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
businesswire.com
IBRX
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA ® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
businesswire.com
IBRX
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
businesswire.com
IBRX
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
prnewswire.com
ONCY
ANIX
ICCM
IBRX
REGN
ONCY
ANIX
ICCM
IBRX
REGN
ImmunityBio’s ANKTIVA ® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
businesswire.com
IBRX
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA ®, NK Cell Therapy Plus Optune Gio ® Device
businesswire.com
IBRX